AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15652441 — intervention group
Group type: COMPARATOR
Intervention: twice-daily CR morphine
Number of subjects: 25
Study 12000207 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 491
Study 12000207 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 491
Study 12000207 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 491
Study 10452766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual standardized Parietaria judaica extract (n = 20)
Number of subjects: 41
Study 10452766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 41
Study 8552268 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg/die monotherapy
Number of subjects: 669
Study 8552268 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg + Hydrochlorothiazide 12.5 mg/die combination
Number of subjects: 669
Study 2201888 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol, Vita‐Glow)
Number of subjects: 38
Study 2201888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 850011 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling
Number of subjects: 48
Study 850011 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Feedback
Number of subjects: 48
Study 850011 — intervention group
Group type: EXPERIMENTAL
Intervention: Role Playing
Number of subjects: 48
Study 850011 — intervention group
Group type: COMPARATOR
Intervention: No Treatment Control
Number of subjects: 48
Study 30702630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 45
Study 30702630 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 45
Study 29170074 — intervention group
Group type: EXPERIMENTAL
Intervention: IV antibiotics for 10 days
Number of subjects: 0
Study 29170074 — intervention group
Group type: EXPERIMENTAL
Intervention: IV antibiotics for 14 days
Number of subjects: 0
Study 29170074 — intervention group
Group type: COMPARATOR
Intervention: IV antibiotics for 21 days
Number of subjects: 0
Study 27473371 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention comprising educational training on HCV, poster and leaflet display, HCV risk prediction algorithm, and patient recall for testing.
Number of subjects: 46
Study 27473371 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 46
Study 23096129 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of AIS (hybrid and pedicle screws alone)
Number of subjects: 33
Study 23096129 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of AIS
Number of subjects: 33
Study 22198675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim on day + 1 (Peg1)
Number of subjects: 53
Study 22198675 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim on day + 4 (Peg4)
Number of subjects: 53
Study 20074355 — intervention group
Group type: EXPERIMENTAL
Intervention: Coercion Experience Scale (CES)
Number of subjects: 102
Study 17409368 — intervention group
Group type: COMPARATOR
Intervention: Physician using no decision support system (DSS)
Number of subjects: 205
Study 17409368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician using unspecified DSS
Number of subjects: 205
Study 17409368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician using DSS from a prestigious medical center
Number of subjects: 205
Study 17409368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician heeding DSS recommendation
Number of subjects: 205
Study 17409368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician defying DSS recommendation with less aggressive treatment
Number of subjects: 205
Study 17409368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician defying DSS recommendation with more aggressive treatment
Number of subjects: 205
Study 16100184 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) at doses > 100 microg
Number of subjects: 8
Study 16100184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14622682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydromorphone (8 mg)
Number of subjects: 0
Study 14622682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil (0.10 microg.kg(‐1).min(‐1))
Number of subjects: 0
Study 14622682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lamotrigine (400 mg)
Number of subjects: 0
Study 14622682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10822390 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of PICP, OC, ICTP and urinary levels of Pyr and Dpyr in patients with OPLL
Number of subjects: 22
Study 10822390 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy males aged 45-78, mean age 63.0 +/- 11.5)
Number of subjects: 22
Study 8896139 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment after cross-over from placebo
Number of subjects: 0
Study 8896139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1855811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 12
Study 6350313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR) and cis-platinum
Number of subjects: 189
Study 6350313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adriamycin or bleomycin, cyclophosphamide, and dactinomycin (BCD)
Number of subjects: 189
Study 6350313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate with citrovorum factor rescue
Number of subjects: 189
Study 31912155 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (30-60 g/d, ∼15% energy)
Number of subjects: 708
Study 31912155 — intervention group
Group type: COMPARATOR
Intervention: Control diet (abstention from walnuts)
Number of subjects: 708
Study 31912155 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (Barcelona cohort)
Number of subjects: 708
Study 31912155 — intervention group
Group type: COMPARATOR
Intervention: Control diet (Barcelona cohort)
Number of subjects: 708
Study 31912155 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain fMRI (subset of Barcelona participants)
Number of subjects: 708
Study 30630722 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (communication, systematic pain management, medication review, activities) with standardized education and on-site training for 4 months.
Number of subjects: 723
Study 30630722 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 723
Study 30630722 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 723
Study 30153111 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 50 mg/day
Number of subjects: 155
Study 30153111 — intervention group
Group type: COMPARATOR
Intervention: Nebivolol, 5 mg/day
Number of subjects: 155
Study 30153111 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 20 mg b.i.d.
Number of subjects: 155
Study 30153111 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 40 mg b.i.d.
Number of subjects: 155
Study 30153111 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 155
Study 27291249 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg once daily and Ribavirin for 12 weeks
Number of subjects: 26
Study 27291249 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg once daily and Ribavirin for 24 weeks
Number of subjects: 26
Study 27291249 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir plus Ribavirin
Number of subjects: 26
Study 27291249 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 26
Study 24467247 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam vapor treatment
Number of subjects: 4
Study 24467247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuuming
Number of subjects: 4
Study 24467247 — intervention group
Group type: COMPARATOR
Intervention: Chemical method (benzalkonium chloride)
Number of subjects: 4
Study 24467247 — intervention group
Group type: COMPARATOR
Intervention: Physical methods (steam vapor and vacuuming)
Number of subjects: 4
Study 22271410 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective TACE targeting the tumor (selective group)
Number of subjects: 124
Study 22271410 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-liver TACE plus chemolipiodolization (whole-liver group)
Number of subjects: 124
Study 22271410 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative TACE or chemolipiodolization)
Number of subjects: 124
Study 19782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioral training (CBT)
Number of subjects: 65
Study 19782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 65
Study 19782343 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (EDU)
Number of subjects: 65
Study 19782343 — intervention group
Group type: COMPARATOR
Intervention: CBT vs EDU
Number of subjects: 65
Study 19782343 — intervention group
Group type: COMPARATOR
Intervention: AR vs EDU
Number of subjects: 65
Study 19782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment for CBT
Number of subjects: 65
Study 19782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment for AR
Number of subjects: 65
Study 19782343 — intervention group
Group type: COMPARATOR
Intervention: Follow-up assessment for EDU
Number of subjects: 65
Study 19782343 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effects across all groups
Number of subjects: 65
Study 16545792 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographic properties of words
Number of subjects: 0
Study 16545792 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16014595 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview identifying residents for hospice care
Number of subjects: 205
Study 11880962 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day treatment with valacyclovir (500 mg twice daily)
Number of subjects: 800
Study 11880962 — intervention group
Group type: COMPARATOR
Intervention: 5-day treatment with valacyclovir (500 mg twice daily)
Number of subjects: 800
Study 9663357 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg once daily (n = 213)
Number of subjects: 432
Study 9663357 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily (after dose doubling if SeDBP >= 90 mm Hg)
Number of subjects: 432
Study 9663357 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 432
Study 9663357 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily (n = 219)
Number of subjects: 432
Study 9663357 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg once daily (after dose doubling if SeDBP >= 90 mm Hg)
Number of subjects: 432
Study 9663357 — intervention group
Group type: COMPARATOR
Intervention: Losartan treatment
Number of subjects: 432
Study 7523547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels measured using the immunometric assay (EIA Test Cyfra 21‐1)
Number of subjects: 584
Study 7523547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels in patients with squamous cell tumors
Number of subjects: 584
Study 7523547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels in patients with adenocarcinomas
Number of subjects: 584
Study 7523547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels in patients with small cell lung cancer (SCLC)
Number of subjects: 584
Study 7523547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21‐1 serum levels across different stages of lung cancer
Number of subjects: 584
Study 3145820 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (30 g i.v. over 30 min)
Number of subjects: 0
Study 3145820 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (500 mg orally)
Number of subjects: 0
Study 3145820 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1‐44 (200 micrograms i.v.)
Number of subjects: 0
Study 30707877 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect energy measurement (metabolic vehicle) group
Number of subjects: 60
Study 30707877 — intervention group
Group type: COMPARATOR
Intervention: Harris‐Benedict formula (HB formula) group
Number of subjects: 60
Study 29437943 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 63
Study 29437943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26910471 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + Ramucirumab (n=43)
Number of subjects: 89
Study 26910471 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel + Placebo (n=46)
Number of subjects: 89
Study 24212915 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) infusion seven days before antiviral therapy
Number of subjects: 85
Study 24212915 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 85
Study 23019296 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 2057
Study 23019296 — intervention group
Group type: COMPARATOR
Intervention: Vaginal micronized progesterone tablets
Number of subjects: 2057
Study 21142534 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 175
Study 21142534 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 175
Study 17545700 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus systemic chemotherapy
Number of subjects: 33
Study 17545700 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 33
Study 15848684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50
Study 15848684 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 50
Study 15848684 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (combined data)
Number of subjects: 50
Study 12200525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP; 500 micro g twice daily, n=14)
Number of subjects: 24
Study 12200525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 24
Study 9833721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical aortic valve
Number of subjects: 40
Study 9833721 — intervention group
Group type: EXPERIMENTAL
Intervention: Homograft aortic valve
Number of subjects: 40
Study 9833721 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 40
Study 7986629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene (OH) twice a week until plaque was present at less than 20% of sites
Number of subjects: 10
Study 7986629 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing at 6 weeks
Number of subjects: 10
Study 7986629 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene (OH) alone
Number of subjects: 10
Study 7986629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with probing depths less than 4 mm at baseline
Number of subjects: 10
Study 7986629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sites with probing depths of 6 mm or more
Number of subjects: 10
Study 3190418 — intervention group
Group type: COMPARATOR
Intervention: 30 rpm cranking rate
Number of subjects: 10
Study 3190418 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 rpm cranking rate
Number of subjects: 10
Study 3190418 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 rpm cranking rate
Number of subjects: 10
Study 29656405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellie Coping Kit for Children with Injury
Number of subjects: 61
Study 7013054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (600 mg daily)
Number of subjects: 50
Study 7013054 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (75 mg daily)
Number of subjects: 50
Study 7013054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid
Number of subjects: 50
Study 31300845 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM delamination (group 2)
Number of subjects: 32
Study 31300845 — intervention group
Group type: COMPARATOR
Intervention: No ILM delamination (group 1)
Number of subjects: 32
Study 28545757 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Childhood Depression (FFT-CD)
Number of subjects: 134
Study 28545757 — intervention group
Group type: COMPARATOR
Intervention: Individual Supportive Psychotherapy (IP)
Number of subjects: 134
Study 26298541 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT plus MBI
Number of subjects: 44
Study 26298541 — intervention group
Group type: COMPARATOR
Intervention: IRT
Number of subjects: 44
Study 23824386 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB/β-TCP
Number of subjects: 434
Study 23824386 — intervention group
Group type: COMPARATOR
Intervention: autograft
Number of subjects: 434
Study 21470608 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2.0 mA for 20 minutes)
Number of subjects: 21
Study 21470608 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study 21470608 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 21
Study 18955513 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional trunk exercises (10 hours of individual and supervised trunk exercises; 30 minutes, 4 times a week, for 5 weeks)
Number of subjects: 33
Study 18955513 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 33
Study 17270679 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐assisted PPV
Number of subjects: 774
Study 17270679 — intervention group
Group type: COMPARATOR
Intervention: Conventional PPV
Number of subjects: 774
Study 16036078 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 16036078 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 16036078 — intervention group
Group type: COMPARATOR
Intervention: Cyclical etidronate
Number of subjects: 0
Study 11433085 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) at 0.8 ± 0.1 mg/kg body weight per day for 3.3 ± 0.6 years
Number of subjects: 11
Study 11433085 — intervention group
Group type: COMPARATOR
Intervention: Control period (before HCTZ therapy)
Number of subjects: 11
Study 9773140 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen (i.v.)
Number of subjects: 42
Study 9773140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7880604 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 20 mg weekly
Number of subjects: 218
Study 7880604 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 20 mg weekly + high-dose medroxyprogesterone acetate (1000 mg daily)
Number of subjects: 218
Study 7880604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 218
Study 7880604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate
Number of subjects: 218
Study 2906479 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine, 1.5 g/day
Number of subjects: 41
Study 2906479 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine, 3 g/day
Number of subjects: 41
Study 31464089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean muscle attenuation (MA)
Number of subjects: 761
Study 31464089 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Number of subjects: 761
Study 31464089 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse performance status (ECOG 1/0), younger age, number of metastatic sites
Number of subjects: 761
Study 31225673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (combined nutraceutical containing bergamot extract, phytosterols, vitamin C, and chlorogenic acid)
Number of subjects: 90
Study 31225673 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose active treatment
Number of subjects: 90
Study 31225673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (low-dose or high-dose)
Number of subjects: 90
Study 31225673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 90
Study 31225673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29181557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multicomponent program implemented for 6 months followed by 6 months without the program
Number of subjects: 398
Study 29181557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multicomponent program
Number of subjects: 398
Study 29181557 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 398
Study 26342904 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-session cognitive dissonance-based (DB) intervention (The PRIDE Body Project©)
Number of subjects: 87
Study 26342904 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 87
Study 23629979 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (8 ml injected into the suprapatellar joint)
Number of subjects: 98
Study 23629979 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP injection)
Number of subjects: 98
Study 21556038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) 28-30 mg/kg/day
Number of subjects: 56
Study 21556038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19687349 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/daily)
Number of subjects: 15
Study 19687349 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients, n=7)
Number of subjects: 15
Study 17045170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐[18F]fluoro‐A‐85380 (2‐[18F]FA)
Number of subjects: 87
Study 14610443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in Project Read (treatment group)
Number of subjects: 165
Study 14610443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in Project Read)
Number of subjects: 165